This clinical trial is focused on studying the long-term safety and how well people tolerate a medication called KarXT in individuals experiencing psychosis associated with Alzheimer’s disease. Psychosis in this context refers to symptoms like hallucinations or delusions that can occur in people with Alzheimer’s disease. The medication being tested, KarXT, is taken in capsule form and contains two active substances: trospium chloride and xanomeline tartrate. These substances are designed to work together to help manage symptoms of psychosis.

The purpose of this study is to understand how safe KarXT is when used over a long period and how well it is tolerated by participants. Participants in the study will take the medication orally, meaning by mouth, in capsule form. The study will last for up to 52 weeks, during which participants will be monitored for any side effects or changes in their condition. Some participants may receive a placebo, which is a capsule that looks like the medication but does not contain the active substances.

Throughout the study, researchers will keep track of any side effects, known as treatment-emergent adverse events (TEAEs), that participants experience. They will also monitor for any serious side effects or any that might lead to stopping the medication. This information will help determine the long-term safety and tolerability of KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to provide valuable insights into the potential benefits and risks of using KarXT for this condition.